Newsletters

[Aptar Pharma] Aptar Pharma, a global leader in drug delivery, announced a collaboration with Aceso Therapeutics, a biotech developing novel therapies for cystic fibrosis to advance the development of ACT-101, designed to target the underlying disease mechanisms.

[United Therapeutics] United Therapeutics Corporation announced that the FDA has accepted the supplemental New Drug Application for nebulized Tyvaso® (treprostinil) to treat idiopathic pulmonary fibrosis, anticipating the agency's review to be complete in late April 2027.

[Immunity] Researchers identified a serotonergic neuroimmune axis, revealing an innate lymphoid cell-driven serotonergic circuit that contributes to asthma pathophysiology and highlights serotonergic signaling as a therapeutic target.

[Signal Transduction and Targeted Therapy] Investigators generated conditional βPIX knockout mice to investigate its contribution to PF pathogenesis, finding progenitor cells in a transitional stem cell state with senescent attributes, along with active, collagen-producing myofibroblasts.

[Ecotoxicology and Environmental Safety] Scientists investigated how prolonged exposure to e-cigarette aerosols affect key cellular pathways involved in antioxidant defense and stemness in human oral and lung epithelial cells.

[Biochemical Pharmacology] The authors examined the interaction between FOXA2 and ST3GAL4 in regulating airway mucus hypersecretion using a murine and NCI-H292 cell model of mucus hypersecretion.

[Cellular Signalling] Researchers explored the function of CDC20 in idiopathic pulmonary fibrosis, finding CDC20 exacerbated pulmonary fibrosis by inhibiting fibroblast autophagy via blocking the mTOR signaling pathway.

[Signal Transduction and Targeted Therapy] The authors integrated multi-omics analysis of human non-small cell lung cancer and identified Mycobacterium abscessus as a microbial determinant of APOBEC3A-associated mutagenesis.

[Cell Reports Medicine] Scientists profiled tumor-intrinsic chromatin accessibility in a patient-derived xenograft biobank and identified recurrent chromatin programs: neuroendocrine, marked by ASCL1/NEUROD1 activity; immunogenic, marked by IRF-associated activity; and stem-like, marked by TEAD/OCT activity.

[Journal for Immunotherapy of Cancer] Researchers used spatial transcriptome, single-cell transcriptome, T-cell receptor repertoire sequencing, bulk RNA transcriptome, phosphorylated proteome, genome mutation, and clinical data to assess the therapeutic and prognostic impact of HIF1A+ CSF3R+ neutrophils in NSCLC, validated in vitro.

[Cell Death & Differentiation] Scientists identified alanyl-tRNA synthetase 1 (AARS1) as a previously unrecognized metabolic effector of KRAS signaling, highlighting the therapeutic potential of targeting AARS1 phosphorylation to overcome drug resistance in lung adenocarcinoma.

[NPJ Precision Oncology] Investigators elucidated the role of Frizzled7 in shaping the immunosuppressive tumor microenvironment and develop a novel bispecific antibody that co-targets Fzd7 and programmed cell death ligand 1.